Outbreak of mass poisoning with anticoagulant rodenticides

Introduction. Rodenticides are pesticides used in the control of rodents. In Russia, only anticoagulant rodenticides are allowed to be used.

Aim: describe a case of mass poisoning with anticoagulant rodenticides.

Main findings. An observation is given of poisoning with anticoagulant rodenticides in 80 people due to the consumption of sunflower oil produced from seeds that have been treated with rodenticides. The victims had a pronounced hemorrhagic syndrome: all had ecchymosis, 79 % had macrohematuria, 1 had uterine bleeding, 3 had intra-abdominal hemorrhages, 16 had nosebleeds, 2 had gastrointestinal bleeding, and 2 had intracerebral hemorrhages. The international normalized ratio (INR) was not definable in 56 patients, while the remaining patients had a median INR of 3.9 (fluctuations from 1.29 to 16.2). Activated partial thromboplastin time (APTT) was not definable in 7 patients; the remaining patients had the median APTT of 65 seconds. Three of the victims died of hemorrhagic syndrome. This article analyzes the conducted therapy. In life-threatening hemorrhagic syndrome induced by rodenticide poisoning or warfarin overdose the drugs of choice are prothrombin complex concentrates and recombinant activated clotting factor VII, but not fresh frozen plasma and vicasol. For long-term therapy, vitamin K1 should be used.

Conflict of interest: the authors declare no conflict of interest.

1. Yakovlev A.A., Babich N.V. Rodenticides. Saint-Petersburg. VIZR; 2011: 63 (In Russian).

2. Yakovlev A.A., Babich N.V. Rodenticides. Plant protection and quarantine. 2011; (10): 42–4 (In Russian).

3. Tasheva M. Anticoagulant Rodenticides. Geneva: WHO; 1995: 123.

4. Huckle K.R., Hutson D.H., Warburton P.A. Elimination and accumulation of the rodenticide fl ocoumafen in rats following repeated oral administration. Xenobiotica. 1988; 18(12): 1465–79. DOI: 10.3109/00498258809042269.

5. Caravati E.M., Erdman A.R., Scharman E.J., et al. Long-acting anticoagulant rodenticide poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007; 45(1): 1–22. DOI: 10.1080/15563650600795487.

6. Chua D.J., Friedenberg W.R. Superwarfarin poisoning. Arch Intern Med. 1998; 158: 1929–32. DOI: 10.1016/s0140-6736(05)70808-4.

7. Parmar G., Bratt H., Moore R., et al. Evidence for common binding site in vivo for the retention of anticoagulants in rat liver. Hum Toxicol. 1987; 6: 431–2.

8. Laas F.J., Forss D.A., Goodfrey M.E.R. Retention of brodifacoum in sheep tissues and excretion in faeces. N Z J Agric Res. 1985; 28: 357–9.

9. Bachmann K.A., Sullivan T.J. Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. Pharmacology. 1983; 27: 281–8.

10. Weitzel J.N., Sadowski J.A., Furie B.C., et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: Clinical and metabolic studies of three cases. Blood. 1990; 76(12): 2555–9. DOI: 10.1182/blood.v76.12.2555.bloodjournal76122555.

11. Stanton T., Sowray P., Mcwaters D., et al. Prolonged anticoagulation with long-acting Coumadin derivatives: Case report of a brodifacoum poisoning with pharmacokinetic data. Blood. 1988; 72: 310A.

12. Bruno G.R., Howland M.A., McMeeking A., et al. Long-acting anticoagulant overdose: Brodifacoum kinetics and optimal vitamin K dosing. Ann Emerg Med. 2000; 36(3): 262–7. DOI: 10.1067/mem.2000.108317.

13. Lefebvre S., Fourel I., Queffélec S., et al. Poisoning by Anticoagulant Rodenticides in Humans and Animals: Causes and Consequences. In: Malangu N, editor. Poisoning — From Specifi c Toxic Agents to Novel Rapid and Simplifi ed Techniques for Analysis. IntechOpen; 2017: 11–32. DOI: 10.5772/intechopen.69955.

14. Mowry J.B., Spyker D.A., Brooks D.E., et al. 2015 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 33rd Annual Report. Clinical Toxicology. Toxicology. 2016; 54(10): 925–1109.

15. Kolosova I.V., Galstyan G.M., Orel E.B., et al. Therapy for the hemorrhagic syndrome caused by defi ciency of vitamin K-dependent coagulation factors (analysis of clinical cases). Gematologiya i transfusiologiya. 2012; 57(2): 22–30 (In Russian).

16. O’Reilly R.A., Aggeler P.M., Gibbs J.O. Hemorrhagic state due to surreptitious ingestion of bishydroxycoumarin. A detailed case study. N Engl J Med. 1962; 267(1): 19–24. DOI: 10.1056/NEJM196207052670105.

17. Andreev N. For the death of the Ulyanians from poisoning with artisanal oil can answer Syzran “Posad”. https://73online.ru/r/za_smert_ulyanovcev_ot_otravleniya_kustarnym_maslom_mozhet_otvetit_syzranskiy_posad-72098 (In Russian).

18. Ermakov V.V., Bolochоvets M.F. Methodological instructions for the determination of zoocoumarin in animal tissues and blood in bait and preparation (penocoumarin) by chromatographic and spectrophotometric methods. № 1550-76 from 20.12.1976 In Methods for determining pesticides in food, feed and environment. Reference publication. Ed. Klisenko M.A. Moscow: Kolos; 1983: 227–30 (In Russian).

19. Spahr J.E., Maul J.S., Rodgers G.M. Superwarfarin Poisoning: A Report of Two Cases and Review of the Literature. Am J Hematol. 2007; 82(9): 656–60. DOI: 10.1002/ajh.20784.

20. Othman N., Chan C.K., Lau F.L. The epidemiology of household rodenticides poisoning in Hong Kong and its risk factors for developing coagulopathy. Hong Kong J Emerg Med. 2014; 21(6): 339–45. DOI: 10.1177/102490791402100601.

21. Chong Y.-K., Mak T.W.-L. Superwarfarin (Long-Acting Anti-coagulant Rodenticides) Poisoning: from Pathophysiology to Laboratory-Guided Clinical Management. Clin Biochem Rev. 2019; 40(4): 175–85. DOI: 10.33176/aacb19-00029.

22. Goldenberg N.A., Manco-johnson M.J. Protein C defi ciency. Haemophilia. 2008; 14(6): 1214–21. DOI: 10.1111/j.1365-2516.2008.01838.x.

23. Umemura Y., Yamakawa K., Kiguchi T., et al. Design and evaluation of new unifi ed criteria for disseminated intravascular coagulation based on the Japanese Association for acute medicine criteria. Clin App Thromb Hemost. 2016; 22(2): 153–60. DOI: 10.1177/1076029615591169.

24. Hayakawa M., Yamakawa K., Kudo D., et al. Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With SepsisInduced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. Clin App Thromb Hemost. 2018; 24(6): 874–83. DOI: 10.1177/1076029618757346.

25. Saja M.F., Abdo A.A., Sanai F.M., et al. The coagulopathy of liver disease: Does vitamin K help? Blood Coagul Fibrinolysis. 2013; 24(1): 10–7. DOI: 10.1097/MBC.0b013e32835975ed.

26. Roberts J.R., Reigart J.R. Recognition and management of pesticide poisonings. 6th ed. Washington: EPA; 2013: 272.

27. Chen T.W., Deng J.F. A brodifacoum intoxication case of mouthful amount. Vet Hum Toxicol. 1986; 22: 488.

28. Donovan J.W., Ballard J.O., Murphy M.J. Brodifacoum therapy with activated charcoal: effect on elimination kinetics. Vet Hum Toxicol. 1990; 32: 350.

29. Goldstein J.N., Thomas S.H., Frontiero V., et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006; 37(1): 151–5. DOI: 10.1161/01.STR.0000195047.21562.23.

30. Holland L.L., Brooks J.P. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006; 126(1): 133–9. DOI: 10.1309/NQXHUG7HND78LFFK.

31. Lee S.B., Manno E.M., Layton K.F., et al. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006; 67(7): 1272–4. DOI: 10.1212/01.wnl.0000238104.75563.2f.

32. Makris M., Greaves M., Phillips W.S., et al. Emergency oral anticoagulant reversal: The relative effi cacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997; 77(3): 477–80. DOI: 10.1055/s-0038-1655992.

33. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic effi ciency. Thromb Res. 1999; 95(4, suppl 1): S7–S12..

34. Boulis N.M., Bobek M.P., Schmaier A., et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999; 45(5): 1113–8.

35. Riess H.B., Meier-Hellmann A., Motsch J., et al. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007; 121(1): 9–16. DOI: 10.1016/j.thromres.2007.02.009.

36. Pabinger I., Brenner B., Kalina U., et al. Prothrombin complex concentrate (Beriplex® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008; 6(4): 622–31. DOI: 10.1111/j.1538-7836.2008.02904.x.

37. Preston F.E., Laidlaw S.T., Sampson B., et al. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): effi cacy and safety in 42 patients. Br J Haematol. 2002; 116(3): 619–24.

38. Imberti D., Barillari G., Biasioli C., et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus. 2011; 9(2): 148–55. DOI: 10.2450/2011.0065-10.

39. Herzog E., Kaspereit F., Krege W., et al. Four-Factor Prothrombin Complex Concentrate (4F-PCC) Is Superior to Three-Factor Prothombin Comlex Concentrates (3F-PCC) for Reversal of Coumarin Anticoagulation. Blood. 2014; 124(21): 1472.

40. Holland L., Warkentin T.E., Refaai M., et al. Suboptimal effect of a threefactor prothrombin complex concentrate (Profi lnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009; 49(6): 1171–7. DOI: 10.1111/j.1537-2995.2008.02080.x.

41. Yuan S., Ferrell C., Chandler W.L. Comparing the prothrombin time INR versus the APTT to evaluate the coagulopathy of acute trauma. Thromb Res. 2007; 120(1): 29–37. DOI: 10.1016/j.thromres.2006.07.002.

42. Makris M., Van Veen J.J. Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? Blood transfus. 2011; 9(2): 117–9. DOI: 10.2450/2011.0111-10.

43. Blacker D.J. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2005; 182(7): 365.

44. Negrier C., Gomperts E., Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia. 2006; 12(S5): 4–13.

45. Skolnick B.E., Mathews D.R., Khutoryansky N.M., et al. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010; 116(5): 693–701. DOI: 10.1182/blood-2009-11-253492.

46. Sørensen B., Johansen P., Nielsen G.L., et al. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinol. 2003; 14(5): 469–77. DOI: 10.1097/00001721-200307000-00007.

47. Galstyan G.M. Label and off-label applications of prothrombin complex concentrates. New perspectives of old drugs. Gematologiya i transfusiologiya. 2018; 63(1): 78–91 (In Russian). DOI: 10.25837/HAT.2018.30..1..008.

48. Schulman S., Furie B. How I treat poisoning with vitamin K antagonists. Blood. 2015; 125(3): 438–42. DOI: 10.1182/blood-2014-08-597781.

49. James D.F. Clinical studies on dicumarol hypoprothrombinemia and vitamin K preparations. Arch Intern Med. 1949; 83(6): 632–56. 50. Udall J.A. Don вЂTM t Use the Wrong Vitamin K. Calif Med. 1970; 112(4): 65–7.

50. Dart R. Medical Toxicology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 1914.

51. Pereslegina I.O., Dubrovina T.S., Zotova S.N. Poisoning of the dog with anticoagulant rodenticide: a clinical case. Veterinaria i kormlenie. 2018; (5): 48–50. DOI: 10.30917/att-vk-1814-9588-2018-5-17 (In Russian).

52. Watson H.G., Baglin T., Laidlaw S.L., et al. A comparison of the effi cacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol. 2001; 115(1): 145–9. DOI: 10.1046/j.1365-2141.2001.03070.x.

53. DeZee K.J., Shimeall W.T., Douglas K.M., et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): A meta-analysis. Arch Intern Med. 2006; 166(4): 391–7. DOI: 10.1001/.391.

54. Nee R., Doppenschmidt D., Donovan D.J., et al. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999; 83(2): 286–8. DOI: 10.1016/S0002-9149(98)00842-X.

55. Hou Y.C., Lin J.L., Huang W.H., et al. Outcomes of patients with acetaminophen-associated toxic hepatitis at a far east poison center. SpringerPlus. 2013; 2(1): 1–7. DOI: 10.1186/2193-1801-2-674.

56. Basic report 35205. Stinging nettles, blanched (Northern Plains Indians). National Nutrient Database for Standard Reference Legacy. USDA website. https: //ndb.nal.usda.gov/ndb/foods/show/306720.2018.

57. Bauman H., Perez J. Food as Medicine: Stinging Nettle (Urtica dioica, Urticaceae). HerbalEGram. 2018; 15(7).